Andrew R. Allen

Closest collaborators

The 19 strongest of 19 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

1. D. Li · 1 shared paper, 2014 · strength 0.04
   • Paper A phase II, open-label, multicenter study to evaluate the antitumor efficacy of CO-1.01 as second-line therapy for gemc… DOI 10.1016/j.pan.2014.07.003↗
2. Eileen Mary O'Reilly · 1 shared paper, 2014 · strength 0.04
   • Paper A phase II, open-label, multicenter study to evaluate the antitumor efficacy of CO-1.01 as second-line therapy for gemc… DOI 10.1016/j.pan.2014.07.003↗
3. David P. Ryan · 1 shared paper, 2014 · strength 0.04
   • Paper A phase II, open-label, multicenter study to evaluate the antitumor efficacy of CO-1.01 as second-line therapy for gemc… DOI 10.1016/j.pan.2014.07.003↗
4. Muhammad Wasif Saif · 1 shared paper, 2014 · strength 0.04
   • Paper A phase II, open-label, multicenter study to evaluate the antitumor efficacy of CO-1.01 as second-line therapy for gemc… DOI 10.1016/j.pan.2014.07.003↗
5. Peter J. Hosein · 1 shared paper, 2014 · strength 0.04
   • Paper A phase II, open-label, multicenter study to evaluate the antitumor efficacy of CO-1.01 as second-line therapy for gemc… DOI 10.1016/j.pan.2014.07.003↗
6. Maeve Aine Lowery · 1 shared paper, 2014 · strength 0.04
   • Paper A phase II, open-label, multicenter study to evaluate the antitumor efficacy of CO-1.01 as second-line therapy for gemc… DOI 10.1016/j.pan.2014.07.003↗
7. Tomislav Dragovich · 1 shared paper, 2014 · strength 0.04
   • Paper A phase II, open-label, multicenter study to evaluate the antitumor efficacy of CO-1.01 as second-line therapy for gemc… DOI 10.1016/j.pan.2014.07.003↗
8. Nathan Bahary · 1 shared paper, 2014 · strength 0.04
   • Paper A phase II, open-label, multicenter study to evaluate the antitumor efficacy of CO-1.01 as second-line therapy for gemc… DOI 10.1016/j.pan.2014.07.003↗
9. Shubham Pant · 1 shared paper, 2014 · strength 0.04
   • Paper A phase II, open-label, multicenter study to evaluate the antitumor efficacy of CO-1.01 as second-line therapy for gemc… DOI 10.1016/j.pan.2014.07.003↗
10. Kenneth H. Yu · 1 shared paper, 2014 · strength 0.04
    • Paper A phase II, open-label, multicenter study to evaluate the antitumor efficacy of CO-1.01 as second-line therapy for gemc… DOI 10.1016/j.pan.2014.07.003↗
11. Daniel A. Laheru · 1 shared paper, 2014 · strength 0.04
    • Paper A phase II, open-label, multicenter study to evaluate the antitumor efficacy of CO-1.01 as second-line therapy for gemc… DOI 10.1016/j.pan.2014.07.003↗
12. Steffen Ormanns · 1 shared paper, 2013 · strength 0.03
    • Paper Randomized, multicenter, phase II study of CO-101 versus gemcitabine in patients with metastatic pancreatic ductal aden… DOI 10.1200/jco.2013.51.0826↗
13. Adam Paul Dicker · 1 shared paper, 2013 · strength 0.03
    • Paper Randomized, multicenter, phase II study of CO-101 versus gemcitabine in patients with metastatic pancreatic ductal aden… DOI 10.1200/jco.2013.51.0826↗
14. Volker Heinemann · 1 shared paper, 2013 · strength 0.03
    • Paper Randomized, multicenter, phase II study of CO-101 versus gemcitabine in patients with metastatic pancreatic ductal aden… DOI 10.1200/jco.2013.51.0826↗
15. Elizabeth A. Poplin · 1 shared paper, 2013 · strength 0.03
    • Paper Randomized, multicenter, phase II study of CO-101 versus gemcitabine in patients with metastatic pancreatic ductal aden… DOI 10.1200/jco.2013.51.0826↗
16. Claudio Bassi · 1 shared paper, 2013 · strength 0.03
    • Paper Randomized, multicenter, phase II study of CO-101 versus gemcitabine in patients with metastatic pancreatic ductal aden… DOI 10.1200/jco.2013.51.0826↗
17. Roland E. Andersson · 1 shared paper, 2013 · strength 0.03
    • Paper Randomized, multicenter, phase II study of CO-101 versus gemcitabine in patients with metastatic pancreatic ductal aden… DOI 10.1200/jco.2013.51.0826↗
18. Harpreet Singh Wasan · 1 shared paper, 2013 · strength 0.03
    • Paper Randomized, multicenter, phase II study of CO-101 versus gemcitabine in patients with metastatic pancreatic ductal aden… DOI 10.1200/jco.2013.51.0826↗
19. Stefan Hubert Boeck · 1 shared paper, 2013 · strength 0.03
    • Paper Randomized, multicenter, phase II study of CO-101 versus gemcitabine in patients with metastatic pancreatic ductal aden… DOI 10.1200/jco.2013.51.0826↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.